These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 27554357)

  • 21. The hunt for antimitotic agents: an overview of structure-based design strategies.
    Dube D; Tiwari P; Kaur P
    Expert Opin Drug Discov; 2016 Jun; 11(6):579-97. PubMed ID: 27077683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hot spot-based design of small-molecule inhibitors for protein-protein interactions.
    Guo W; Wisniewski JA; Ji H
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2546-54. PubMed ID: 24751445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening-based approaches to identify small molecules that inhibit protein-protein interactions.
    Choi S; Choi KY
    Expert Opin Drug Discov; 2017 Mar; 12(3):293-303. PubMed ID: 28067063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating Experimental and In Silico HTS in the Discovery of Inhibitors of Protein-Nucleic Acid Interactions.
    Li Q; Folly da Silva Constantino L; Spies MA
    Methods Enzymol; 2018; 601():243-273. PubMed ID: 29523234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
    Kumalo HM; Bhakat S; Soliman ME
    Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-based evolution of a promiscuous inhibitor to a selective stabilizer of protein-protein interactions.
    Sijbesma E; Visser E; Plitzko K; Thiel P; Milroy LG; Kaiser M; Brunsveld L; Ottmann C
    Nat Commun; 2020 Aug; 11(1):3954. PubMed ID: 32770072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
    Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
    J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.
    Li H; Xiao H; Lin L; Jou D; Kumari V; Lin J; Li C
    J Med Chem; 2014 Feb; 57(3):632-41. PubMed ID: 24456369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surfing the Protein-Protein Interaction Surface Using Docking Methods: Application to the Design of PPI Inhibitors.
    Sable R; Jois S
    Molecules; 2015 Jun; 20(6):11569-603. PubMed ID: 26111183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In silico carborane docking to proteins and potential drug targets.
    Calvaresi M; Zerbetto F
    J Chem Inf Model; 2011 Aug; 51(8):1882-96. PubMed ID: 21774557
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel approaches for targeting the adenosine A2A receptor.
    Yuan G; Gedeon NG; Jankins TC; Jones GB
    Expert Opin Drug Discov; 2015 Jan; 10(1):63-80. PubMed ID: 25311639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings.
    Nandekar PP; Sangamwar AT
    Expert Opin Drug Discov; 2012 Sep; 7(9):771-89. PubMed ID: 22716293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The conformational musings of a medicinal chemist.
    Finch H
    Drug Discov Today; 2014 Mar; 19(3):320-5. PubMed ID: 24184532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPCR crystal structures: Medicinal chemistry in the pocket.
    Shonberg J; Kling RC; Gmeiner P; Löber S
    Bioorg Med Chem; 2015 Jul; 23(14):3880-906. PubMed ID: 25638496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of machine learning approaches for novel drug discovery.
    Lima AN; Philot EA; Trossini GH; Scott LP; Maltarollo VG; Honorio KM
    Expert Opin Drug Discov; 2016; 11(3):225-39. PubMed ID: 26814169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
    Levoin N; Vo DD; Gautier F; Barillé-Nion S; Juin P; Tasseau O; Grée R
    Bioorg Med Chem; 2015 Apr; 23(8):1747-57. PubMed ID: 25797160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. X-ray crystallography over the past decade for novel drug discovery - where are we heading next?
    Zheng H; Handing KB; Zimmerman MD; Shabalin IG; Almo SC; Minor W
    Expert Opin Drug Discov; 2015; 10(9):975-89. PubMed ID: 26177814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational modulator design by exploitation of protein-protein complex structures.
    Wichapong K; Poelman H; Ercig B; Hrdinova J; Liu X; Lutgens E; Nicolaes GA
    Future Med Chem; 2019 May; 11(9):1015-1033. PubMed ID: 31141413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.